Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells

mAbs

Volumn 9, Issue 1, 2017, Pages 114-126

  Grugan, Katharine D ^a   Dorn, Keri ^a   Jarantow, Stephen W ^a   Bushey, Barbara S ^a   Pardinas, Jose R ^a   Laquerre, Sylvie ^a   Moores, Sheri L ^a   Chiu, Mark L ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Antibody dependent cell mediated cytotoxicity; antibody dependent cell mediated phagocytosis; bispecific; c Met; EGFR; Fc engineering; hemi afucosylated; low fucose

Indexed keywords

BISPECIFIC ANTIBODY; CD14 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GREEN FLUORESCENT PROTEIN; JNJ 61186372; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; IMMUNOGLOBULIN FC FRAGMENT; JNJ-61186372; MET PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOWN REGULATION; FUCOSYLATION; GENOTYPE; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; IMMUNOLOGY; LUNG TUMOR; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LUNG NEOPLASMS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85002289039     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1249079     Document Type: Article

References (50)

1. Society AC. Cancer Facts & Figures 2015. Atlanta:American Cancer Society, 2015.
2. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology:a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015; 5:2892-911; PMID:26609494
3. Castanon E, Martin P, Rolfo C, Fusco JP, Ceniceros L, Legaspi J, Santisteban M, Gil-Bazo I. Epidermal Growth Factor Receptor targeting in non-small cell lung cancer:revisiting different strategies against the same target. Curr Drug Targets 2014; 15:1273-83; PMID:25511613; http://dx.doi.org/10.2174/138945011514141216092935
4. Politi K, Ayeni D, Lynch T. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Cancer Cell 2015; 27:751-3; PMID:26058074; http://dx.doi.org/10.1016/j.ccell.2015.05.012
5. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73; PMID:15737014; http://dx.doi.org/10.1371/journal.pmed.0020073
6. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26; PMID:21430269; http://dx.doi.org/10.1126/scitranslmed.3002003
7. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17:77-88; PMID:20129249; http://dx.doi.org/10.1016/j.ccr.2009.11.022
8. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011; 6:2011-7; PMID:22052230; http://dx.doi.org/10.1097/JTO.0b013e31823ab0dd
9. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009; 19:542-51; PMID:19758803; http://dx.doi.org/10.1016/j.tcb.2009.07.002
10. Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer:a meta-analysis of published literatures. PLoS One 2014; 9:e99399; PMID:24922520; http://dx.doi.org/10.1371/journal.pone.0099399
11. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000; 275:8806-11; PMID:10722725; http://dx.doi.org/10.1074/jbc.275.12.8806
12. Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008; 99:911-22; PMID:19238632; http://dx.doi.org/10.1038/sj.bjc.6604559
13. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932-7; PMID:18093943; http://dx.doi.org/10.1073/pnas.0710370104
14. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43; PMID:17463250; http://dx.doi.org/10.1126/science.1141478
15. Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer 2014; 5:745-53; PMID:25368674; http://dx.doi.org/10.7150/jca.9696
16. Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 2013; 32:5593-601; PMID:23812422; http://dx.doi.org/10.1038/onc.2013.245
17. Lee BS, Kim HJ, Hwang JW, Cheong KH, Kim KA, Cha HY, Lee JM, Kim CH. The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer. Ann Surg Oncol 2016; 23:2046-53; PMID:26812910; http://dx.doi.org/10.1245/s10434-015-5084-0
18. Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res 2016 Jul 1; 76(13):3942-53; http://dx.doi.org/10.1158/0008-5472.CAN-15-2833
19. Grugan KD, McCabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, van Rooijen N, Anderson GM, Nemeth JA, Strohl WR, et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J Immunol 2012; 189:5457-66; PMID:23105143; http://dx.doi.org/10.4049/jimmunol.1201889
20. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets:cancer as a paradigm. Nat Immunol 2010; 11:889-96; PMID:20856220; http://dx.doi.org/10.1038/ni.1937
21. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723-37; PMID:21997792; http://dx.doi.org/10.1038/nri3073
22. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20:436-43; PMID:18585454; http://dx.doi.org/10.1016/j.coi.2008.05.012
23. Derer S, Kellner C, Berger S, Valerius T, Peipp M. Fc engineering:design, expression, and functional characterization of antibody variants with improved effector function. Methods Mol Biol 2012; 907:519-36; PMID:22907372; http://dx.doi.org/10.1007/978-1-61779-974-7_30
24. Nimmerjahn F, Gordan S, Lux A. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 2015; 36:325-36; PMID:25981969; http://dx.doi.org/10.1016/j.it.2015.04.005
25. Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs 2012; 4:326-40; PMID:22531441; http://dx.doi.org/10.4161/mabs.19941
26. Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2014; 65:114-26; PMID:23872058; http://dx.doi.org/10.1016/j.ymeth.2013.06.035
27. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
28. Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs 2013; 5:872-81; PMID:23995614; http://dx.doi.org/10.4161/mabs.26307
29. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
30. Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, Gerritsen AF, Schuurman J, Parren PW. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc 2014; 9:2450-63; PMID:23995617; http://dx.doi.org/10.1038/nprot.2014.169
31. Jarantow SW, Bushey BS, Pardinas JR, Boakye K, Lacy ER, Sanders R, Sepulveda MA, Moores SL, Chiu ML. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody. J Biol Chem 2015; 290:24689-704; PMID:26260789; http://dx.doi.org/10.1074/jbc.M115.651653
32. Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology 2011; 21:1087-96; PMID:21470983; http://dx.doi.org/10.1093/glycob/cwr047
33. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013; 122:3482-91; PMID:24106207; http://dx.doi.org/10.1182/blood-2013-05-504043
34. Nesspor TC, Raju TS, Chin CN, Vafa O, Brezski RJ. Avidity confers FcgammaR binding and immune effector function to aglycosylated immunoglobulin G1. J Mol Recognit 2012; 25:147-54; PMID:22407978; http://dx.doi.org/10.1002/jmr.2155
35. Jeffers M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med (Berl) 1996; 74:505-13; PMID:26811110; http://dx.doi.org/10.1007/BF00204976
36. Bertotti A, Sassi F. Molecular Pathways:Sensitivity and Resistance to Anti-EGFR Antibodies. Clin Cancer Res 2015; 21:3377-83; PMID:26071484; http://dx.doi.org/10.1158/1078-0432.CCR-14-0848
37. Sgambato A, Casaluce F, Maione P, Rossi A, Ciardiello F, Gridelli C. Cetuximab in advanced non-small cell lung cancer (NSCLC):the showdown? J Thoracic Dis 2014; 6:578-80; PMID:24976974; http://dx.doi.org/10.3978/j.issn.2072-1439.2014.06.14
38. Losanno T, Rossi A, Maione P, Napolitano A, Gridelli C. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer. Exp Opin Biol Ther 2016; 16:747-58; PMID:26950292; http://dx.doi.org/10.1517/14712598.2016.1163333
39. Charakidis M, Boyer M. Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer? Transl Lung Cancer Res 2014; 3:395-6; PMID:25806331; http://dx.doi.org/10.3978/j.issn.2218-6751.2014.09.03
40. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Jr., Blumenschein GR, Jr., Krzakowski MJ, Robinet G, Godbert B, Barlesi F, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31:4105-14; PMID:24101053; http://dx.doi.org/10.1200/JCO.2012.47.4189
41. Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer:the fall of Icarus? Expert Rev Anticancer Ther 2015; 15:487-9; PMID:25818471; http://dx.doi.org/10.1586/14737140.2015.1031219
42. Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 2015; 25:1325-34; PMID:26263923; http://dx.doi.org/10.1093/glycob/cwv065
43. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol 2012; 7:1596-602; PMID:22747430; http://dx.doi.org/10.1021/cb300130k
44. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979-89; PMID:12527303; http://dx.doi.org/10.1016/S0022-2836(02)01250-0
45. Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 2014; 192:2252-60; PMID:24489098; http://dx.doi.org/10.4049/jimmunol.1301249
46. Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, Dubinsky WP, Strohl WR, Jordan RE, Zhang N, et al. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res 2012; 14:R116; PMID:22873525; http://dx.doi.org/10.1186/bcr3240
47. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362-71; http://dx.doi.org/10.4049/jimmunol.177.1.362
48. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor:implications for the mechanisms of action. Cancer Res 2006; 66:7630-8; PMID:16885363; http://dx.doi.org/10.1158/0008-5472.CAN-05-4010
49. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011 Sep; 187(6):3383-90; PMID:21832160; http://dx.doi.org/10.4049/jimmunol.1003926
50. Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, et al. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling. Cancer Res 2015; 75:3373-83; PMID:26141862; http://dx.doi.org/10.1158/0008-5472.CAN-15-0356